Navigation Links
Replidyne to Report 2007 Fourth Quarter and Year-End Earnings

Presenting at BIO CEO & Investor Conference

LOUISVILLE, Colo., Feb. 5 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) announced today that it will host a conference call on Tuesday, February 26, 2008 at 4:45 P.M. ET to report 2007 fourth quarter and year-end earnings. Additionally, Replidyne will present at an upcoming investor conference in February 2008.

Earnings conference call information is as follows:

Kenneth J. Collins, President and CEO, and other members of Replidyne's

senior management team will provide a company update and discuss

earnings results via conference call and webcast on Tuesday, February 26,

2008, at 4:45 P.M. ET. Callers may participate in the conference call by

dialing 866-510-0707 (domestic) or 617-597-5376 (international), and

providing the passcode 33794809. To access the live webcast, please log

on to the company's website at and go to the

Investor Relations section.

A replay of the conference call will be available approximately one hour

after completion of the call through Tuesday, March 11, 2008 at midnight.

Callers may access the replay by dialing 888-286-8010 (U.S.

participants) or 617-801-6888 (international participants). The audio

replay passcode is 92464480. To access a replay of the webcast, visit

the Investor Relations section of the company's website at

Investor conference presentation information is as follows:

-- Mr. Collins will present on Tuesday, February 12, 2008 at 2:45 P.M. ET

at the BIO CEO & Investor Conference, to be held at the Waldorf-Astoria

in New York City. A live audio webcast of this presentation will be

available on the investor relations section of the company's website at The webcast will be archived and available on

Replidyne's website after the event for a period of 30 days.

-- At the same conference, Replidyne's Chief Commercial Officer Peter

Letendre, Pharm.D. will participate on antibiotics panel "Super Drugs

Against Super Bugs" on Wednesday, February 13, 2008 at 9:30 A.M.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead product, faropenem medoxomil, is a novel oral community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and C. difficile-associated disease (CDAD). Replidyne is pursuing the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research.

Safe Harbor

This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company's ability to obtain a new partner for faropenem on acceptable terms; the Company's ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company's product candidates and the Company's ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company's ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company's sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company's most recent Form 10-Q filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are available through the SEC's electronic data gather analysis and retrieval system (EDGAR) at All forward-looking statements made in the press release are made as of the date hereof and the Company assumes no obligation to update the forward-looking statements in the document.

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Replidyne to Announce Third Quarter 2007 Earnings
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
(Date:10/13/2015)... ... , ... Clinovo recently appointed Jeff Parr and Ed Donaldson to its Business ... business. , Jeff Parr has spent the past decade providing quality management software and ... and Ab Sciex to name a few. He is based in Salt Lake ...
(Date:10/13/2015)... -- the United States , ... about 14% of all new cases of kidney cancer.   ... and Europe .  PRCC represents about ... Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that ... (publ) ("AstraZeneca") have completed enrolment in a global Phase II study ...
(Date:10/12/2015)... NEW YORK , Oct. 12, 2015 ... its segments, which include cell type, products, applications, end-user ... REPORT HIGHLIGHTS The global cell expansion ... and is expected to reach revenues of $9.7 billion ... compound annual growth rate (CAGR) of 17.8% from 2015 ...
(Date:10/12/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... developing and commercializing novel treatments in oncology, endocrinology and ... Turpin , the Company,s former Senior Vice President, Chief ... Quebec City office.  ... Officer of the Company commented, "After a comprehensive review, ...
Breaking Biology Technology:
(Date:9/30/2015)... 2015  With nearly 300,000 Americans living with spinal ... estimated to reach 12,500 annually, the role of Independent ... for Independent Living (SCRS-IL) is increasingly important. SCRS-IL ... opening doors to independence for individuals with ... notably assistive technology services and education. "In ...
(Date:9/29/2015)... 2015 News facts: ... saving energy , Minimized design shrinks PC footprint ... Mode and embedded Fujitsu PalmSecure authentication enable enterprises to ... today shows that good things come in small packages, ... its enterprise desktop and mobile portfolio. Featuring workplace design ...
(Date:9/28/2015)... NEW YORK , Sept. 28, 2015 /PRNewswire/ ... rate, respiration rate and body temperature, is an ... signs can be indicators of deterioration in a ... the hospital, vital signs are typically taken during ... eight hours. If a patient deteriorates between these ...
Breaking Biology News(10 mins):